Italy Insulin Drugs and Delivery Devices Market Size (2024 - 2029)

The Italy Insulin Drugs and Delivery Devices Market is projected to experience growth over the forecast period, driven by advancements in technology and the adoption of innovative devices that offer greater comfort to patients. The market's expansion is supported by the country's healthcare framework, which provides essential medical assistance, including free insulin pens for diabetic patients, while adhering to specific guidelines. Additionally, initiatives to enhance health literacy and urban health programs contribute to the overall market dynamics, reflecting a structured approach to healthcare delivery across different regions in Italy.

Home Market Analysis Healthcare Research Device Drug Combination Research Diagnostics and Therapeutics Research Diabetes Care Research Insulin Drugs And Delivery Devices Market in Italy Market Size

Market Size of Italy Insulin Drugs and Delivery Devices Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Italy Insulin Drugs and Delivery Devices Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 531.86 Million
Market Size (2029) USD 572.96 Million
CAGR (2024 - 2029) 1.50 %

Major Players

Italy Insulin Drugs and Delivery Devices Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Italy Insulin Drugs And Delivery Devices Market Analysis

The Italy Insulin Drugs and Delivery Devices Market size is estimated at USD 531.86 million in 2024, and is expected to reach USD 572.96 million by 2029, growing at a CAGR of 1.5% during the forecast period (2024-2029).

Between February and March 2021, the Italian Association of Diabetes Doctors (AMD) conducted a survey among its members to assess the impact of the SARS-CoV-2 pandemic on the volume of care provided by diabetes services in Italy, as well as to analyse the measures implemented during the national lockdown. Through planning, urban health initiatives promote healthy lifestyles. Health literacy refers to an individual's ability to comprehend, access, and apply information in ways that promote and maintain good health. Italy has joined the Action Network on Measuring Population and Organizational Health Literacy (M-POHL), which conducted a survey between 2019 and 2021 to establish a baseline level of health literacy that can be used to plan health policy measures to improve health literacy and track the health outcomes of such measures over time.

The National Health Program is structured in essential levels of assistance that can be defined differently in the various regions. The National Health Program is structured in LEAs (essential levels of assistance). LEAs define all the medical assistance modalities offered by the INHS offers to citizens, with or without partial contributions based on a patient's income. The Insulin pens are free of cost for all diabetic patients in Italy, but they must still adhere to a nominal set of medical assistance guidelines that remain free of charge.

Technological development is gaining momentum in the insulin devices market. Over the years, in fact, several technological innovations have been developed that have led to the creation of new types of devices that are more comfortable for patients compared to the traditional ones. Such advantages have helped the rise in the adoption of these products in the Italian market.

Italy Insulin Drugs And Delivery Devices Industry Segmentation

Italy's Insulin Drugs and Delivery Devices Market witnessed USD 0.4 billion in the current year. Italy's Insulin Drugs and Delivery Devices Market is segmented into Drugs (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, and Biosimilar Insulins), Devices (Insulin Pens, Insulin Pumps, Insulin Syringes, and Jet Injectors). The report offers the value (in USD million) and volume (in million mL) for insulin drugs and (in unit million) for the devices for the above segments.

Drug
Basal or Long-acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast-acting Insulins
NovoRapid/Novolog (Insulin aspart)
Humalog (Insulin lispro)
Apidra (Insulin glulisine)
FIASP (Insulin aspart)
Admelog (Insulin lispro Sanofi)
Traditional Human Insulins
Novolin/Mixtard/Actrapid/Insulatard
Humulin
Insuman
Combination Insulins
NovoMix (Biphasic Insulin aspart)
Ryzodeg (Insulin degludec and Insulin aspart)
Xultophy (Insulin degludec and Liraglutide)
Soliqua/Suliqua (Insulin glargine and Lixisenatide)
Biosimilar Insulins
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Device
Insulin Pumps
Insulin Pump Devices
Insulin Pump Reservoirs
Insulin Infusion sets
Insulin Pens
Cartridges in reusable pens
Disposable insulin pens
Insulin Syringes
Insulin Jet Injectors
Need A Different Region Or Segment?
Customize Now

Italy Insulin Drugs and Delivery Devices Market Size Summary

The Italy Insulin Drugs and Delivery Devices Market is poised for steady growth over the forecast period, driven by advancements in technology and a well-structured healthcare system. The market benefits from the Italian National Healthcare Service's universal coverage, ensuring that individuals with diabetes have access to necessary medications and devices without out-of-pocket expenses. The decentralized nature of the Italian health system, with significant administrative powers held by regional authorities, allows for tailored diabetes care strategies. The National Diabetes Plan further enhances the quality of care by focusing on patient-centered approaches. Technological innovations in insulin delivery devices, such as insulin pumps, are gaining traction due to their ability to provide continuous and more accurate insulin administration, reducing the discomfort and variability associated with traditional methods.

The market landscape is characterized by a consolidated structure with a few major players, including Roche, Medtronics, Novo Nordisk, Sanofi, and Eli Lilly. Recent mergers and collaborations, such as those between Eli Lilly and Boehringer Ingelheim, and Novo Nordisk and Ypsomed, have strengthened the market presence of these companies. The development of integrated automated insulin delivery systems, like the one announced by CamDiab and Ypsomed, highlights the ongoing commitment to enhancing diabetes management through smart, connected solutions. These advancements are expected to drive the adoption of insulin delivery devices, contributing to the market's growth trajectory in Italy.

Explore More

Italy Insulin Drugs and Delivery Devices Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

    3. 1.3 Market Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Drug

      1. 2.1.1 Basal or Long-acting Insulins

        1. 2.1.1.1 Lantus (Insulin Glargine)

        2. 2.1.1.2 Levemir (Insulin Detemir)

        3. 2.1.1.3 Toujeo (Insulin Glargine)

        4. 2.1.1.4 Tresiba (Insulin Degludec)

        5. 2.1.1.5 Basaglar (Insulin Glargine)

      2. 2.1.2 Bolus or Fast-acting Insulins

        1. 2.1.2.1 NovoRapid/Novolog (Insulin aspart)

        2. 2.1.2.2 Humalog (Insulin lispro)

        3. 2.1.2.3 Apidra (Insulin glulisine)

        4. 2.1.2.4 FIASP (Insulin aspart)

        5. 2.1.2.5 Admelog (Insulin lispro Sanofi)

      3. 2.1.3 Traditional Human Insulins

        1. 2.1.3.1 Novolin/Mixtard/Actrapid/Insulatard

        2. 2.1.3.2 Humulin

        3. 2.1.3.3 Insuman

      4. 2.1.4 Combination Insulins

        1. 2.1.4.1 NovoMix (Biphasic Insulin aspart)

        2. 2.1.4.2 Ryzodeg (Insulin degludec and Insulin aspart)

        3. 2.1.4.3 Xultophy (Insulin degludec and Liraglutide)

        4. 2.1.4.4 Soliqua/Suliqua (Insulin glargine and Lixisenatide)

      5. 2.1.5 Biosimilar Insulins

        1. 2.1.5.1 Insulin Glargine Biosimilars

        2. 2.1.5.2 Human Insulin Biosimilars

    2. 2.2 Device

      1. 2.2.1 Insulin Pumps

        1. 2.2.1.1 Insulin Pump Devices

        2. 2.2.1.2 Insulin Pump Reservoirs

        3. 2.2.1.3 Insulin Infusion sets

      2. 2.2.2 Insulin Pens

        1. 2.2.2.1 Cartridges in reusable pens

        2. 2.2.2.2 Disposable insulin pens

      3. 2.2.3 Insulin Syringes

      4. 2.2.4 Insulin Jet Injectors

Italy Insulin Drugs and Delivery Devices Market Size FAQs

The Italy Insulin Drugs and Delivery Devices Market size is expected to reach USD 531.86 million in 2024 and grow at a CAGR of 1.5% to reach USD 572.96 million by 2029.

In 2024, the Italy Insulin Drugs and Delivery Devices Market size is expected to reach USD 531.86 million.

Italy Insulin Drugs And Delivery Devices Market Report Snapshots

Italy Insulin Drugs And Delivery Devices Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)